CellaVision AB has received its first major order to a veterinary laboratory chain in the US market. The order supplies equipment to multiple laboratories and will be delivered before the end of this year. As the veterinary market is still relatively small and is characterized by few large customers, an order of this size should be seen as a one-time event. The order has a value of about 10 million SEK. Additional sales to the customer's remaining laboratories depend on certain evaluations that will be conducted in 2015. With a positive outcome, the majority of the chain's laboratories may be equipped with CellaVision® DM9600 Vet and CellaVision®1200 Vet. Since 2012, CellaVision has developed systems specifically for the veterinary market. Since then, the company has entered the US market which is characterized by a few large laboratory chains which together have about a hundred laboratories having significant sample volumes, primarily from dogs and cats. "We are very pleased to have partnered with our first major customer in veterinary medicine. Globally, the market is still relatively small since few countries have a consolidated laboratory market as in the US. We need relatively large sample volumes to create interest in the digital analysis of white and red cells in the blood. The long-term trend, however, is that laboratories outside North America will also consolidate to larger units, "says Yvonne Mårtensson, CEO of CellaVision. CellaVision DM9600 Vet and DM1200 Vet replaces a manual microscope for blood analysis in the veterinary laboratories. The products are an adapted version of CellaVision's existing instruments for human blood with the capacity to analyze blood from the most common pets, ie dog and cat. The primary target group is the approximately 100 larger veterinary laboratories in the US and Canada, where the volume of samples is high and the need for an effective analytical method is great. One key driver is CellaVision software for remote CellaVision® Remote Review Software, which allows for external devices to access test results and cell images. In Europe and in other geographic markets, blood analysis for animals is performed, but in most cases they are not consolidated in reference laboratories. Instead they are typically performed in veterinary clinics or hospital laboratories. CellaVision sells the product directly to end customers. For further information, please contact: Yvonne Mårtensson, CEO, CellaVision AB Phone: +46 708 33 77 82. Email: yvonne.martensson@cellavision.com About CellaVision CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2013 sales were SEK 180 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries/supportoffices in the USA, Canada, Japan and China. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com. This information was released for public disclosure on December 11, 2014 at 08.20 pm CET. [HUG#1879035]
CellaVision AB receives its first major order for the
Top 10 Most Recent News Articles
Voter Events by Valley Community Healthcare Aim to Empower
Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....
Continue Reading
LG OLED evo W6: UAE Roadshow Starts with a Bang
They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...
Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest
A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...
Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring
Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...
Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors
Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...
Continue Reading
Hyliion Class Action Deadline Nears for Investors
Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...
Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil
Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...
Continue ReadingTop 5 Most Recently Viewed Articles
Zepp Health Corp Posts Mixed Q3 Results Amid Product Launches
Financial Overview of Zepp Health Corporation's Third Quarter Zepp Health Corporation (NYSE: ZEPP) recently released its unaudited financial results for the third quarter. The company's revenues totaled $42.5 million with a basic and diluted net loss per share recorded at $0.05, translating to a net loss of $13.3 million. Notably, these figures reflect a challenge the...
Continue Reading
Artea Bank to Ignite Third Fund for Apartment Building Renovation
Artea Bank Launches New Fund for Multi-Apartment Building Renovations AB Artea Bankas has announced its intention to establish a third fund aimed at modernizing multi-apartment buildings. This initiative follows a notification from the European Investment Bank (EIB), signaling the start of negotiations for this new venture. Projected assets for the fund are substantial,...
Continue Reading
Insights on PROCEPT BioRobotics Quarterly Earnings Forecast
Expected Earnings Report for PROCEPT BioRobotics PROCEPT BioRobotics (NASDAQ: PRCT) has set the stage for its next quarterly earnings report, which is eagerly anticipated by investors. The earnings release is scheduled for an upcoming Monday, an event that this company looks forward to with optimism. Market analysts currently predict that PROCEPT BioRobotics will post an...
Continue Reading
Akebia Therapeutics' New Stock Offering Aims for Growth
Akebia Unveils New Public Offering of Common Stock Akebia Therapeutics, Inc. (Nasdaq: AKBA), a dedicated biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, has publicly announced the pricing details of its recent offering. This offering involves 25 million shares of common stock, each priced at $2.00, aiming to generate...
Continue Reading
Crédit Agricole SA Announces Adjustment in Liquidity Contract
Crédit Agricole SA Adjusts Liquidity Contract with Kepler Cheuvreux In a significant move, Crédit Agricole S.A. has announced a reduction of resources available for its liquidity contract with Kepler Cheuvreux. This shift aims to enhance the market activity surrounding the shares of the company, providing better stability and trading conditions in the financial market....
Continue Reading